Filing Flows › UroGen Pharma (URGN) › Zusduri revenue
UroGen Pharma (URGN) Zusduri revenue by quarter
UroGen Pharma's Zusduri revenue was $68.0M in Q3 2026 (third quarter 2026), +35% from Q2 2026. Over the last 5 quarters it ranged from $1.8M (Q3 2025) to $68.0M (Q3 2026).
| Quarter | Zusduri revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $68.0M | +35% | 38× |
| Q2 2026 | $50.4M | +72% | — |
| Q1 2026 | $29.2M | +109% | — |
| Q4 2025 | $14.0M | +688% | — |
| Q3 2025 | $1.8M | — | — |
Q3 2026 at a glance
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is UroGen Pharma's Zusduri revenue?
UroGen Pharma's Zusduri revenue was $68.0M in Q3 2026 (third quarter 2026), +35% from Q2 2026.
How has UroGen Pharma's Zusduri revenue changed?
Over the last 5 quarters it ranged from $1.8M (Q3 2025) to $68.0M (Q3 2026).